Next Article in Journal
In Vivo Estimation of Ketogenesis Using Metabolic Flux Analysis—Technical Aspects and Model Interpretation
Next Article in Special Issue
Metabolomics Studies in Psoriatic Disease: A Review
Previous Article in Journal
Application of Lipid Class Ratios for Sample Stability Monitoring—Evaluation of Murine Tissue Homogenates and SDS as a Stabilizer
Previous Article in Special Issue
Alterations of Extracellular Matrix Components in the Course of Juvenile Idiopathic Arthritis
 
 
Article
Peer-Review Record

A Metabolomic Profile Predictive of New Osteoporosis or Sarcopenia Development

Metabolites 2021, 11(5), 278; https://doi.org/10.3390/metabo11050278
by Kana Miyamoto 1, Akiyoshi Hirayama 2, Yuiko Sato 3,4,5, Satsuki Ikeda 2, Midori Maruyama 2, Tomoyoshi Soga 2, Masaru Tomita 2, Masaya Nakamura 3, Morio Matsumoto 3, Noriko Yoshimura 6 and Takeshi Miyamoto 1,3,4,5,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Metabolites 2021, 11(5), 278; https://doi.org/10.3390/metabo11050278
Submission received: 4 April 2021 / Revised: 26 April 2021 / Accepted: 26 April 2021 / Published: 28 April 2021
(This article belongs to the Special Issue Biomarkers and Human Blood Metabolites)

Round 1

Reviewer 1 Report

metabolites-1191112

Metabolomic profile predictive of new osteoporosis or sarcopenia development

 

The manuscript provides a revised version of the manuscript “Metabolomic profile predictive of new osteoporosis or sarcopenia development”. The manuscript has been improved considerably and my comments have been adequately addressed.

Author Response

  1. The manuscript provides a revised version of the manuscript “Metabolomic profile predictive of new osteoporosis or sarcopenia development”. The manuscript has been improved considerably and my comments have been adequately addressed.

Reply: We thank you for valuable comments and appreciate this response.

Reviewer 2 Report

The authors have addressed most of my concerns during last round of review. However, I still have strong concerns for the conclusion that Gly and taurine as predictors because of the small sample size and the values of the Odds ratio and 95% confidence interval. Therefore, I suggest the authors to weaken the conclusion throughout the manuscript including title and abstracct. Maybe it is better to state that the changes of  Gly and taurine are associated with the disease rather than state that they are predictors. 

Author Response

  1. The authors have addressed most of my concerns during last round of review. However, I still have strong concerns for the conclusion that Gly and taurine as predictors because of the small sample size and the values of the Odds ratio and 95% confidence interval. Therefore, I suggest the authors to weaken the conclusion throughout the manuscript including title and abstracct. Maybe it is better to state that the changes of Gly and taurine are associated with the disease rather than state that they are predictors.

Reply: We thank the reviewer for valuable comments that helped us improve our manuscript. We understand that our sample size is limited, and that values of the odds ratio and 95% interval are significant but small. However, ours was a longitudinal prospective study, and new osteoporosis or sarcopenia development was evident at the third survey in subjects who exhibited lower Gly or higher taurine, respectively, at the second survey during four-year follow-up. Moreover, logistic regression analysis demonstrated that low Gly or high taurine significantly predicted new osteoporosis or new sarcopenia development, respectively, at the third survey, even after adjustment for age, sex and BMI. Thus we feel that our original usage of the word “predict” is appropriate. However, we agree with your comments regarding small sample size and odds ratio and now state that in the Abstract, saying, “Although sample size and odds ratios are small….”, and state that low Gly or high taurine are “predictive” rather than “predictor” in the title and abstract. We also change the title to “A Metabolomic Profile Predictive of New Osteoporosis or Sarcopenia Development”.

Back to TopTop